# RAPSON (NCT03230734)

> Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: radium-223 plus docetaxel
- Indication: symptomatic bone-only metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03230734
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: Radium-223; Docetaxel
- Enrollment: 70
- Primary outcome: health-related quality of life (HRQoL) clinical benefit
- Primary outcome: health-related quality of life (HRQoL ) clinical benefit

## Indexed commentary on RAPSON so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rapson-nct03230734

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03230734", "email": "<work email>"}; the inbox owner confirms by the emailed link.